As a result, TIDE score is now becoming a more reasonable and accurate method in assessing the outcome of immunotherapy and prognosis of patients compared with the single evaluation of PD-L1 levels, tumor mutational burden, or IFN-γ signature (39). The gene discussed is IFNG; the disease is neoplasm.